BillionToOne(NASDAQ) BLLN

BillionToOne helps pregnant women and cancer patients with simple blood tests. These tests count DNA molecules to find health issues early. This lets families and doctors plan better medical care.

What’s in the Kit?

• UNITY Complete: Non-invasive prenatal screen evaluating fetal risk for aneuploidies, which are abnormal chromosome counts, and other genetic conditions; generated 89% of revenue in the first quarter of 2026.
• Northstar Select: Liquid biopsy blood test identifying tumor mutations to guide cancer treatment; part of the oncology segment that contributed 10% of revenue in the first quarter of 2026.
• Northstar Response: Assay quantifying the amount of cancer in the body using methylation, a chemical signal, to monitor how well therapy works.
• Unity Confirm: Simple maternal blood test launched in May 2026 to confirm high-risk screening results without the risks of invasive procedures.

Scaling Up and Reaching Out

• Launched the Northstar Select and Northstar Response liquid biopsy tests in 2023 to enter the cancer diagnostics market.
• Partnered with Johnson & Johnson in January 2023 to provide clinical trial support and testing services.
• Collaborated with Johnson & Johnson in July 2025 to develop a companion diagnostic, which is a test used to match patients with specific medicines.
• Expanded laboratory capacity in 2023 by opening a 90,000 square foot facility in Union City, California.
• Introduced Northstar PGx in January 2026 and Northstar Select CH in February 2026 to improve chemotherapy safety and detect blood-related mutations.

Counting Molecules for High Precision

The company uses a unique platform to count cell-free DNA—tiny pieces of DNA floating in the blood—with high accuracy. It improves operational efficiency by using artificial intelligence to handle insurance claims and manage laboratory tasks.

Strong Growth and New Profits

• Revenue grew to $108.4 million in the first quarter of 2026, up 83.8% from $59 million in the same period of 2025.
• Gross profit reached $79.1 million in the first quarter of 2026, an increase of 108.3% year-over-year.
• Net income improved to $18 million in the first quarter of 2026, compared to a loss of $4 million in the first quarter of 2025.
• Free cash flow rose to $11 million in the first quarter of 2026, up from zero in the prior year period.

Bottom Line

BillionToOne has evolved from a research firm into a commercial business with established products in prenatal and cancer screening. Its focus on automated precision testing and efficient operations has led the company to recent profitability.